– Three brand new presentations to showcase emerging evidence of VRDN-001 efficacy and differentiation –
– VRDN-001 10 mg/kg Proof-of-Concept Data from Ongoing Phase 1/2 Study in Thyroid Ophthalmic Disease Selected for Current Presentation –
– Mechanistic Characterization of VRDN-001, a Potential Best-in-Class Full Antagonist of IGF-1R Selected for Oral Highlighted Late Presentation –
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) — Viridian Therapeutics, Inc. VRDNa biotechnology company advancing new treatments for patients suffering from serious diseases unmet by current therapies, today announced that three abstracts highlighting the potential benefits of VRDN-001 will be featured as Oral Featured and Breaking News poster presentations to be presented at the 91st Annual Meeting of the American Thyroid Association (ATA) being held October 19-23, 2022 in Montreal, Canada.
“We are pleased to present mechanistic and clinical data at this year’s ATA Annual Meeting that contribute to new insights that support the differentiation of VRDN-001 from current therapies,” said Jonathan Violin, Ph.D., President and President of Viridian Therapeutics CHAIRMAN. “We are thrilled that the 10mg/kg data from our Phase 1/2 study has been selected for an late-breaking presentation and we look forward to providing further updates for VRDN-001 and VRDN-002 later this quarter to introduce. These updates will include top-line data for the 20 mg/kg cohort of our ongoing Phase 1/2 study of VRDN-001 in thyroid eye disease, followed by top-line data from the currently enrolled 3-mg /kg cohort later this quarter. We will also be reporting additional pharmacokinetic and pharmacodynamic results from our first human study of VRDN-002, our extended half-life IGF-1R antibody, that support and build on the recently presented interim results.”
Oral Highlighted Poster Session Details:
| Title: | VRDN-001, a fully antagonistic antibody to insulin-like growth factor receptor-1 (IGF-1R) in… |
